REGIMEN STUDY GROUPS Absolute termination of arrhythmias (min) Mean±S.D. Absolute termination of myoclonismus (min) Mean±S.D. PROPHYLACTIC (Medication given at 15 min before furosemide) CONTROL – saline Not determined Not determined BPC 157 No arrhythmias † No myoclonus† L-NAME Not determined Not determined L-NAME + BPC 157 9.2±2.3 † 13.3±3.4 † L-arginine 26.3±3.1 † 18.6±2.1 † L-arginine + BPC 157 5.3±3.7 † 7.1±2.5 † L-NAME + L-arginine Not determined Not determined L-NAME + L-arginine + BPC 157 No arrhythmias † No myoclonus† THERAPEUTIC (Medication given at 90 min after furosemide) CONTROL – saline Not determined Not determined BPC 157 4.9±0.1 † 9.5±2.5 † L-NAME Not determined Not determined L-NAME + BPC 157 13.3±2.2 † 19.9±4.1 † L-arginine 31.1±4.5 † 25.8±3.8 † L-arginine + BPC 157 10.5±2.9 † 13.5±3.1 † L-NAME + L-arginine Not determined Not determined L-NAME + L-arginine + BPC 157 8.2±1.9 † 11.2±3.4 †

Table 9: Absolute termination of furosemide-induced hypokalemic arrhythmias and myoclonismus after application of pentadecapeptide BPC 157 (10 μg/kg i.p.), L-NAME (5 mg/kg i.p.), inhibitor of NO-synthase, and L-arginine (100 mg/kg i.p.), substrate of NO-synthase and NO-precursor. †P<0.05 at least vs. control.